NCT06080984 is a Phase 1 clinical trial of Oncolytic Virus SDJ001 in Malignant Tumor, sponsored by West China Hospital.

Who is sponsoring NCT06080984?

NCT06080984 is sponsored by West China Hospital.

What drugs are being tested in NCT06080984?

Interventions in NCT06080984: Oncolytic Virus SDJ001, Oncolytic Virus YD06-1.

What condition does NCT06080984 study?

NCT06080984 studies Malignant Tumor.

Is NCT06080984 still recruiting?

NCT06080984 is currently status unknown. Last updated 12 October 2023.

Last reviewed 2023-10-12 · How we verify

NCT06080984

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

The Application of Novel Oncolytic Virus in Late Stage Solid Tumors

Status unknown Phase 1 Last updated 12 October 2023

What this trial tests

Phase 1 trial testing Oncolytic Virus SDJ001 in Malignant Tumor in 24 participants. Status unknown.

Timeline

15 October 2023

Primary endpoint
15 October 2024

15 October 2025

Quick facts

Lead sponsor	West China Hospital
Phase	Phase 1
Status	Status unknown
Study type	INTERVENTIONAL
Allocation	non randomized
Design	parallel
Masking	none
Primary purpose	treatment
Enrollment	24
Start date	15 October 2023
Primary completion	15 October 2024
Estimated completion	15 October 2025
Sites	1 location across China

Drugs / interventions tested

Oncolytic Virus SDJ001 — full drug profile →
Oncolytic Virus YD06-1 — full drug profile →

Conditions studied

Malignant Tumor — all drugs for Malignant Tumor →

Sponsor

West China Hospital

Who can join

18 and older, any sex, with Malignant Tumor. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The purpose of this study is to evaluate the efficacy and safety of novel oncolytic virus in late stage solid tumors.

Publications & conference data

4 peer-reviewed publications reference this trial (live from Europe PMC):

Preclinical and clinical evaluation of intratumoral injection of an IL-12 expressing SKV-012 oncolytic virus for advanced solid tumors.
Jiang Z, Yang N, Jin J, Zhang Z, et al · · 2025 · cited 4× · PMID 40484644 · DOI 10.1136/jitc-2025-011642
A Comprehensive Review of Modern Cancer Therapies Utilizing Oncolytic Viruses.
Sułek M, Szuster-Ciesielska A. · · 2025 · cited 1× · PMID 41294877 · DOI 10.3390/cells14221825
Bioinspired micro- and nanostructured systems for cancer therapy.
Yang R, Zhang B, Fei X, Cong S, et al · · 2024 · cited 1× · PMID 39619230 · DOI 10.1002/mco2.70025
Combination of Vaccine With IL-12-Armed Oncolytic Virus SKV-012 Synergistically Potentiates Immune Responses in HPV-Associated Malignancies.
Yang N, Xu L, Zheng M, Lu H, et al · · 2026 · PMID 41987850 · DOI 10.1002/mco2.70737

Verify or expand the search:

Other recruiting trials for Malignant Tumor

Currently open trials in the same condition.

NCT07193329 — Psychological Distress in Malignant Tumor Patients: Effects on Treatment Adherence, Outcomes, and Quality of Life · recruiting
NCT06618274 — Effectiveness of Central Oncology Navigation and the Use of an ORN · NA · recruiting
NCT06674889 — Rehabilitation Outcomes Study · NA · recruiting
NCT05862259 — A Real-world Study of the Efficacy and Safety of ICIs as First-line Therapy for Advanced Malignancies · recruiting
NCT05596344 — Long-term Follow-up of Anxiety and Depression in Patients With Malignant Tumors · recruiting

Other West China Hospital trials

Trials by the same sponsor.

NCT07583654 — Safety, Tolerability, and Preliminary Antitumor Activity of Cationic Peptide-IL22BP mRNA in Advanced Solid Tumors · Phase 1 · not yet recruiting
NCT07583914 — Safety, Tolerability, and Preliminary Antitumor Activity of Non-Cationic Peptide-CD47 siRNA in Advanced Solid Tumors · Phase 1 · not yet recruiting
NCT07492914 — Neoadjuvant Sacituzumab Govitecan Plus Tagitanlimab for Resectable Head and Neck Squamous Cell Carcinoma · Phase 2 · recruiting
NCT07507097 — Study on the Optimal Head Position for Patients With Severe Acute Ischemic Stroke · NA · not yet recruiting
NCT07472933 — Vebotolimab Combined With Ptorlimab for EGFR-positive Refractory Advanced Biliary Tract Malignancies · Phase 2 · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT06080984 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by West China Hospital
Last refreshed: 12 October 2023

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06080984.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing